Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

With this milestone, VG801 now holds RMAT, Rare Pediatric Disease, and Orphan Drug designations. VeonGen has also been selected to collaborate with the FDA under the Rare Disease Endpoint Advancement ...

Trouble seeing in dim light or at night may indicate night blindness (nyctalopia), which can stem from vitamin A deficiency, ...

The Driving and Vehicle Licensing Agency (DVLA) could slap drivers with a £1,000 fine if they fail to report certain health conditions to the motoring authority.